174 related articles for article (PubMed ID: 34896093)
1. Early Radiographic Progression of Scleroderma: Lung Disease Predicts Long-term Mortality.
Volkmann ER; Tashkin DP; Roth MD; Goldin J; Kim GHJ
Chest; 2022 May; 161(5):1310-1319. PubMed ID: 34896093
[TBL] [Abstract][Full Text] [Related]
2. Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts.
Volkmann ER; Tashkin DP; Sim M; Li N; Goldmuntz E; Keyes-Elstein L; Pinckney A; Furst DE; Clements PJ; Khanna D; Steen V; Schraufnagel DE; Arami S; Hsu V; Roth MD; Elashoff RM; Sullivan KM;
Ann Rheum Dis; 2019 Jan; 78(1):122-130. PubMed ID: 30409830
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosuppression in the Scleroderma Lung Study II.
Goldin JG; Kim GHJ; Tseng CH; Volkmann E; Furst D; Clements P; Brown M; Roth M; Khanna D; Tashkin DP
Ann Am Thorac Soc; 2018 Nov; 15(11):1286-1295. PubMed ID: 30265153
[TBL] [Abstract][Full Text] [Related]
4. Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease.
Volkmann ER; Tashkin DP; Roth MD; Clements PJ; Khanna D; Furst DE; Mayes M; Charles J; Tseng CH; Elashoff RM; Assassi S
Arthritis Res Ther; 2016 Dec; 18(1):305. PubMed ID: 28038680
[TBL] [Abstract][Full Text] [Related]
5. Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II.
Volkmann ER; Tashkin DP; Li N; Roth MD; Khanna D; Hoffmann-Vold AM; Kim G; Goldin J; Clements PJ; Furst DE; Elashoff RM
Arthritis Rheumatol; 2017 Jul; 69(7):1451-1460. PubMed ID: 28376288
[TBL] [Abstract][Full Text] [Related]
6. Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II.
Volkmann ER; Tashkin DP; Sim M; Li N; Khanna D; Roth MD; Clements PJ; Hoffmann-Vold AM; Furst DE; Kim G; Goldin J; Elashoff RM
J Rheumatol; 2019 Oct; 46(10):1316-1325. PubMed ID: 30770517
[TBL] [Abstract][Full Text] [Related]
7. Improved Cough and Cough-Specific Quality of Life in Patients Treated for Scleroderma-Related Interstitial Lung Disease: Results of Scleroderma Lung Study II.
Tashkin DP; Volkmann ER; Tseng CH; Roth MD; Khanna D; Furst DE; Clements PJ; Theodore A; Kafaja S; Kim GH; Goldin J; Ariolla E; Elashoff RM
Chest; 2017 Apr; 151(4):813-820. PubMed ID: 28012804
[TBL] [Abstract][Full Text] [Related]
8. The MUC5B promoter variant does not predict progression of interstitial lung disease in systemic sclerosis.
Volkmann ER; Tashkin DP; Roth MD; Li N; Charles J; Mayes M; Kim G; Goldin J; Pourzand L; Clements PJ; Furst DE; Khanna D; Elashoff RM; Assassi S
Semin Arthritis Rheum; 2020 Oct; 50(5):963-967. PubMed ID: 32906032
[TBL] [Abstract][Full Text] [Related]
9. Sex differences in clinical outcomes and biological profiles in systemic sclerosis-associated interstitial lung disease: a post-hoc analysis of two randomised controlled trials.
Volkmann ER; Tashkin DP; Silver R; Bostwick CF; Assassi S; Frost DB; Leng M; Wilhalme H; Kim GH; Goldin J; Roth MD
Lancet Rheumatol; 2022 Oct; 4(10):e668-e678. PubMed ID: 37745675
[TBL] [Abstract][Full Text] [Related]
10. Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis.
Tashkin DP; Volkmann ER; Tseng CH; Kim HJ; Goldin J; Clements P; Furst D; Khanna D; Kleerup E; Roth MD; Elashoff R
Ann Rheum Dis; 2016 Feb; 75(2):374-81. PubMed ID: 25452309
[TBL] [Abstract][Full Text] [Related]
11. Cyclophosphamide for connective tissue disease-associated interstitial lung disease.
Barnes H; Holland AE; Westall GP; Goh NS; Glaspole IN
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD010908. PubMed ID: 29297205
[TBL] [Abstract][Full Text] [Related]
12. Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18.
Volkmann ER; Tashkin DP; Kuwana M; Li N; Roth MD; Charles J; Hant FN; Bogatkevich GS; Akter T; Kim G; Goldin J; Khanna D; Clements PJ; Furst DE; Elashoff RM; Silver RM; Assassi S
Arthritis Rheumatol; 2019 Dec; 71(12):2059-2067. PubMed ID: 31233287
[TBL] [Abstract][Full Text] [Related]
13. Interstitial Lung Disease: How Should Therapeutics Be Implemented?
Bruni C; Campochiaro C; de Vries-Bouwstra JK
Rheum Dis Clin North Am; 2023 May; 49(2):279-293. PubMed ID: 37028835
[TBL] [Abstract][Full Text] [Related]
14. Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and Research.
Hoffmann-Vold AM; Brunborg C; Airò P; Ananyeva LP; Czirják L; Guiducci S; Hachulla E; Li M; Mihai C; Riemekasten G; Sfikakis PP; Valentini G; Kowal-Bielecka O; Allanore Y; Distler O;
Chest; 2023 Mar; 163(3):586-598. PubMed ID: 36244404
[TBL] [Abstract][Full Text] [Related]
15. Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis.
Shenoy PD; Bavaliya M; Sashidharan S; Nalianda K; Sreenath S
Arthritis Res Ther; 2016 Jun; 18(1):123. PubMed ID: 27255492
[TBL] [Abstract][Full Text] [Related]
16. Association of Symptoms of Gastroesophageal Reflux, Esophageal Dilation, and Progression of Systemic Sclerosis-Related Interstitial Lung Disease.
Volkmann ER; Tashkin DP; Leng M; Kim GHJ; Goldin J; Roth MD
Arthritis Care Res (Hoboken); 2023 Aug; 75(8):1690-1697. PubMed ID: 36504432
[TBL] [Abstract][Full Text] [Related]
17. Radiographic fibrosis score predicts survival in systemic sclerosis-associated interstitial lung disease.
Takei R; Arita M; Kumagai S; Ito Y; Tokioka F; Koyama T; Saito R; Nishimura K; Tokumasu H; Ishida T
Respirology; 2018 Apr; 23(4):385-391. PubMed ID: 28925574
[TBL] [Abstract][Full Text] [Related]
18. Use of mycophenolate mofetil for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: Information from a Japanese hospital claims database.
Funatogawa T; Narita Y; Tamura A; Mii K; Sugitani Y; Uchida T
Mod Rheumatol; 2022 Jul; 32(4):755-760. PubMed ID: 34850080
[TBL] [Abstract][Full Text] [Related]
19. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.
Tashkin DP; Roth MD; Clements PJ; Furst DE; Khanna D; Kleerup EC; Goldin J; Arriola E; Volkmann ER; Kafaja S; Silver R; Steen V; Strange C; Wise R; Wigley F; Mayes M; Riley DJ; Hussain S; Assassi S; Hsu VM; Patel B; Phillips K; Martinez F; Golden J; Connolly MK; Varga J; Dematte J; Hinchcliff ME; Fischer A; Swigris J; Meehan R; Theodore A; Simms R; Volkov S; Schraufnagel DE; Scholand MB; Frech T; Molitor JA; Highland K; Read CA; Fritzler MJ; Kim GHJ; Tseng CH; Elashoff RM;
Lancet Respir Med; 2016 Sep; 4(9):708-719. PubMed ID: 27469583
[TBL] [Abstract][Full Text] [Related]
20. Using Transitional Changes on High-Resolution Computed Tomography to Monitor the Impact of Cyclophosphamide or Mycophenolate Mofetil on Systemic Sclerosis-Related Interstitial Lung Disease.
Kim GHJ; Tashkin DP; Lo P; Brown MS; Volkmann ER; Gjertson DW; Khanna D; Elashoff RM; Tseng CH; Roth MD; Goldin JG
Arthritis Rheumatol; 2020 Feb; 72(2):316-325. PubMed ID: 31430058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
